For decades, ALS has been a death sentence.
Two to three years from diagnosis. No cure. No effective treatment. Just manage the decline.
That just changed.
The FDA just granted fast-track designation to CK0803, an experimental T-cell therapy for ALS.
Not another drug. Not another pill. A cell therapy that reprograms the immune system to stop attacking the nervous system.
The results from early trials:
60% reduction in neurofilament light chain — a marker of nerve cell damage.
200% increase in IL-10 — an anti-inflammatory protein.
Slowed disease progression in patients who were declining rapidly.
The therapy uses regulatory T-cells from donated umbilical cords. No donor matching needed. Off-the-shelf. Ready to use.
The cells are engineered to seek out inflammation in the brain and spinal cord. To suppress the overactive immune response. To restore balance.
The MedBed community has always said that the body can heal itself if given the right tools. Now they are giving patients the tools to heal their own nervous system.
They are not calling it a MedBed. They are calling it “T-cell therapy.”
But the result is the same.
The immune system can be reprogrammed. The body can be taught to heal itself.
And Big Pharma knows it.
🔗 M-B Technology
MedBedTechnology
